Sigrid Jall

Sigrid Jall

Auto-generated profile, based on publicly available information

Sigrid Jall

Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), 85764 Neuherberg, Germany; Division of Metabolic Diseases, Department of Medicine, Technische Universität München, 80333 Munich, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Cell
Verified
Journal Article
Closed access
BFBrian Finan
Brian Finan
CCChristoffer Clemmensen
Christoffer Clemmensen
ZZZhimeng Zhu
Zhimeng Zhu
KSKerstin Stemmer
Kerstin Stemmer
KGKarine Gauthier
Karine Gauthier
TMTimo D. Müller
Timo D. Müller

1 May 2017 in Molecular Metabolism
Verified
Journal Article
Open access
SJSigrid Jall
Sigrid Jall
SSStephan Sachs
Stephan Sachs
CCChristoffer Clemmensen
Christoffer Clemmensen
BFBrian Finan
Brian Finan
FNFrauke Neff
Frauke Neff
SHSusanna M. Hofmann
Susanna M. Hofmann
Obesity is a major health threat that affects men and women equally. Despite this fact, weight-loss potential of pharmacotherapies is typically first evaluated in male mouse models of diet-induced obesity (DIO). To address this disparity we herein determined whether a monomeric peptide with agonism at the receptors for glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon is equally efficient in correcting DIO, dyslipidemia, and glucose metabolism in DIO female mice as it has been previously established for DIO male mice. Female C57BL/6J mice and a cohort of fatmass-matched C57BL/6J male mice were treated for 27 days via subcutaneous injections with either the GLP-1/GIP/glucagon triagonist or PBS. A second cohort of C57BL/6J male mice was included to match the females in the duration of the high-fat, high-sugar diet (HFD) exposure. Our results show that GLP-1/GIP/glucagon triple agonism inhibits food intake and decreases body weight and body fat mass with comparable potency in male and female mice that have been matched for body fat mass. Treatment improved dyslipidemia in both sexes and reversed diet-induced steatohepatitis to a larger extent in female mice compared to male mice. We herein show that a recently developed unimolecular peptide triagonist is equally efficient in both sexes, suggesting that this polypharmaceutical strategy might be a relevant alternative to bariatric surgery for the treatment of obesity and related metabolic disorders.

20 September 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
KMKristina M. Mueller
Kristina M. Mueller
KHKerstin Hartmann
Kerstin Hartmann
DKDoris Kaltenecker
Doris Kaltenecker
SVSabine Vettorazzi
Sabine Vettorazzi
MBMandy Bauer
Mandy Bauer
RMRichard Moriggl
Richard Moriggl
Glucocorticoids (GCs) are important regulators of systemic energy metabolism, and aberrant GC action is linked to metabolic dysfunctions. Yet, the extent to which normal and pathophysiological energy metabolism depend on the GC receptor (GR) in adipocytes remains unclear. Here, we demonstrate that adipocyte GR deficiency in mice significantly impacts systemic metabolism in different energetic states. Plasma metabolomics and biochemical analyses revealed a marked global effect of GR deficiency on systemic metabolite abundance and, thus, substrate partitioning in fed and fasted states. This correlated with a decreased lipolytic capacity of GR-deficient adipocytes under postabsorptive and fasting conditions, resulting from impaired signal transduction from β-adrenergic receptors to adenylate cyclase. Upon prolonged fasting, the impaired lipolytic response resulted in abnormal substrate utilization and lean mass wasting. Conversely, GR deficiency attenuated aging-/diet-associated obesity, adipocyte hypertrophy, and liver steatosis. Systemic glucose tolerance was improved in obese GR-deficient mice, which was associated with increased insulin signaling in muscle and adipose tissue. We conclude that the GR in adipocytes exerts central but diverging roles in the regulation of metabolic homeostasis depending on the energetic state. The adipocyte GR is indispensable for the feeding-fasting transition but also promotes adiposity and associated metabolic disorders in fat-fed and aged mice.

17 May 2016 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
AHA Hinney
A Hinney
MKMiriam Kesselmeier
Miriam Kesselmeier
SJS Jall
S Jall
ASAlbert Smith
Albert Smith
MFM Föcker
M Föcker
JHJ Hebebrand
J Hebebrand

23 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCChristoffer Clemmensen
Christoffer Clemmensen
SJSigrid Jall
Sigrid Jall
MKMaximilian Kleinert
Maximilian Kleinert
CQCarmelo Quarta
Carmelo Quarta
TGTim Gruber
Tim Gruber
MTMatthias H. Tschöp
Matthias H. Tschöp
Pharmacological stimulation of brown adipose tissue (BAT) thermogenesis to increase energy expenditure is progressively being pursued as a viable anti-obesity strategy. Here, we report that pharmacological activation of the cold receptor transient receptor potential cation channel subfamily M member 8 (TRPM8) with agonist icilin mimics the metabolic benefits of cold exposure. In diet-induced obese (DIO) mice, treatment with icilin enhances energy expenditure, and decreases body weight, without affecting food intake. To further potentiate the thermogenic action profile of icilin and add complementary anorexigenic mechanisms, we set out to identify pharmacological partners next to icilin. To that end, we specifically targeted nicotinic acetylcholine receptor (nAChR) subtype alpha3beta4 (α3β4), which we had recognized as a potential regulator of energy homeostasis and glucose metabolism. Combinatorial targeting of TRPM8 and nAChR α3β4 by icilin and dimethylphenylpiperazinium (DMPP) orchestrates synergistic anorexic and thermogenic pathways to reverse diet-induced obesity, dyslipidemia, and glucose intolerance in DIO mice.

1 October 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
SSStephan Sachs
Stephan Sachs
LNLili Niu
Lili Niu
PGPhilipp Geyer
Philipp Geyer
SJSigrid Jall
Sigrid Jall
MKMaximilian Kleinert
Maximilian Kleinert
SHSusanna M. Hofmann
Susanna M. Hofmann
Aims: Unimolecular peptides targeting the receptors for glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) (GLP‐1/GIP co‐agonist) have been shown to outperform each single peptide in the treatment of obesity and cardiometabolic disease in preclinical and clinical trials. By combining physiological treatment endpoints with plasma proteomic profiling (PPP), we aimed to identify biomarkers to advance non‐invasive metabolic monitoring of compound treatment success and exploration of ulterior treatment effects on an individual basis. Materials and methods: We performed metabolic phenotyping along with PPP in body weight‐matched male and female diet‐induced obese (DIO) mice treated for 21 days with phosphate‐buffered saline, single GIP and GLP‐1 mono‐agonists, or a GLP‐1/GIP co‐agonist. Results: GLP‐1R/GIPR co‐agonism improved obesity, glucose intolerance, non‐alcoholic fatty liver disease (NAFLD) and dyslipidaemia with superior efficacy in both male and female mice compared with mono‐agonist treatments. PPP revealed broader changes of plasma proteins after GLP‐1/GIP co‐agonist compared with mono‐agonist treatments in both sexes, including established and potential novel biomarkers for systemic inflammation, NAFLD and atherosclerosis. Subtle sex‐specific differences have been observed in metabolic phenotyping and PPP. Conclusions: We herein show that a recently developed unimolecular GLP‐1/GIP co‐agonist is more efficient in improving metabolic disease than either mono‐agonist in both sexes. PPP led to the identification of a sex‐independent protein panel with the potential to monitor non‐invasively the treatment efficacies on metabolic function of this clinically advancing GLP‐1/GIP co‐agonist.